InduPro, Inc. is a biotechnology company that develops novel therapeutics for cancer and autoimmune diseases by defining and harnessing inherent and induced proximity biology. Their proprietary platforms, Membrane Interactomics (MInt) and Proximity Modalities (ARRIS), utilize AI and machine learning to map cell-surface protein spatial relationships, enabling the discovery of selective co-target pairs for precision drug development. The company's pipeline includes bispecific antibodies, multispecific antibodies, and antibody-drug conjugates.